Skip to content
Open access · OA via OpenAlex

#972 Epigenetic clock and Fabry disease

Ersilia Paparazzo, Mirella Aurora Aceto, Teresa Serra Cassano, Gemma Antonucci, Silvana Geracitano, Simona Granata, Rosita Greco, Antonella La Russa, Giuseppe Passarino, Gianluigi Zaza, Alberto Montesanto

Nephrology Dialysis Transplantation · 2025

Abstract

Abstract Background and Aims Fabry's disease (FD) is a rare X-linked, lysosomal accumulation genetic disorder due to deficiency of the enzyme α-galactosidase-A due to pathogenic mutations in the GLA gene (Xq22.1). Due to these mutations, globotriaosylceramide (Gb3) and its deacylated form, globotriaosylsphingosine (lysoGb3), gradually accumulate within the lysosomes of various cells. The potential pathogenicity and clinical relevance of D313Y variation in patients with FD remains debated. D313Y patients do not show clear signs of alpha-galactosidase A deficiency and Gb3 accumulation at an early stage. For this reason, other molecular biomarkers are required for patient risk stratification. The development and application of epigenetic predictors, for healthcare research has grown dramatically over the last decade. These markers also known as epigenetic clocks, can aid FD risk stratification as they resulted to be very accurate for estimating biological age in different diseases. However, data on the epigenetic clock(definition) in Fabry disease are still lacking. Our working hypothesis is that the application of epigenetic clocks to quantify the biological age of Fabry patients could provide independent prognostic information for disease risk stratification in patients harboring the D313Y mutation. Therefore, we developed a mathematical model for biological age prediction in healthy individuals and applied it to blood samples from FD patients with the D313Y mutation to identify patterns of accelerated aging. Method The epigenetic clock was developed in a healthy cohort of 201 healthy subjects. FD sample was represented by a cohort including 25 untreated FD patients harboring the D313Y mutation. Genomic DNA from whole blood was extracted using a standard commercial kit. The clock includes five DNAm biomarkers strongly correlated with chronological age (ELOVL2, C1orf132, FHL2, KLF14 and TRIM59). Methylation levels were measured by using a SNaPshot assay and then through the Illumina Methylation EPICv2 Array technology. Results We found a strong correlation between the epigenetic clock and chronological age in DNA samples from healthy subjects (r = 0.97) (Fig. 1). Then, the formulated clock was applied to estimate biological age of patients harboring the D313Y mutation. These patients generally did not show clinical manifestations conformable with FD (enzymatic activity and lyso-Gb3 in plasma within normal limits). 7 patients did not present any sign of disease, 12 neurologic manifestations, 4 renal failure and 2 cerebrovascular events. Surprisingly, the epigenetic age of Fabry patients did not deviate significantly from that of healthy subjects of the same age (Fig. 2). These results were confirmed by epigenetics clocks estimated through EPICv2 methylation assay (Illumina). To further explore the role of the selected epigenetic markers in FD, we analyzed the DNA methylation levels of the 5 genes included in the clock. Only three of these (C1orf132, TRIM59, and KLF14) showed lower age-adjusted methylation levels in FD patients than in healthy subjects (P ≤ 0.001 SNaPshot assay) (Fig. 3). Conclusion To the best of our knowledge this is the first time that an epigenetic clock has been used to FD patient risk stratification. Although a clear direct relationship between epigenetic age and chronological age was not found, we identified epigenetic markers in TRIM59, C1orf132 and KLF14 that might contribute to improving the clinical characterization of FD patients with D313Y mutation. These three genes showed lower methylation levels in FD patients that might be cause an increased expression of the corresponding products. Further studies in additional cohorts are required to verify if monitoring epigenetic age over time might be a useful strategy to identify D313Y-positive patients with latent or early-FD pathology and to clarify the role of the investigated epigenetic biomarkers in

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/ndt/gfaf116.1021
Canonical
link ↗
Fetched
2026-10-14 MST

Cite this

APA
Paparazzo, E., Aceto, M.A., Cassano, T.S., Antonucci, G., Geracitano, S., Granata, S., Greco, R., Russa, A.L., Passarino, G., Zaza, G., &amp; Montesanto, A. (2025). #972 Epigenetic clock and Fabry disease. <em>Nephrology Dialysis Transplantation</em>. https://doi.org/10.1093/ndt/gfaf116.1021
Vancouver
Paparazzo E, Aceto MA, Cassano TS, Antonucci G, Geracitano S, Granata S, et al. #972 Epigenetic clock and Fabry disease. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf116.1021.
BibTeX
@article{ersilia2025Epigen, title = {#972 Epigenetic clock and Fabry disease}, author = {Ersilia Paparazzo and Mirella Aurora Aceto and Teresa Serra Cassano and Gemma Antonucci and Silvana Geracitano and Simona Granata and Rosita Greco and Antonella La Russa and Giuseppe Passarino and Gianluigi Zaza and Alberto Montesanto}, journal = {Nephrology Dialysis Transplantation}, year = {2025}, doi = {10.1093/ndt/gfaf116.1021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings